Reduced Nicotine Cigarettes in Smokers With and Without Alcohol Use Disorder

Alcohol Drinking Clinical Trial

— RedNic  

Official title:

Reduced Nicotine Cigarettes in Smokers With and Without Alcohol Use Disorder

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02990455
• Other study ID #: BMI-202181
• Status: Completed
• Phase: Phase 1
• Start date: November 14, 2017
• Est. completion date: April 21, 2021

Study information

• Verified date: September 2021
• Source: Battelle Memorial Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The proposed research will investigate whether smokers with vs. without current at-risk alcohol drinking (ARD) respond to reduced nicotine cigarettes by increasing their alcohol consumption or smoke exposure, thereby diminishing the hypothesized public health benefit of these new products.

Description:

The current proposal examines response to two RNCs, one with low nicotine content (RNC Low; 0.03mg) and one with moderate nicotine content (RNC Moderate; 0.8mg) in daily smokers with and without ARD. Participants (N = 70) will attend a total of five visits to the laboratory. The first visit will be to classify participants as either ARD (n = 35) or Non ARD (n = 35) and gather baseline data. Participants will be assigned to undergo two experimental conditions (i.e., exclusive smoking of RNC Low or Moderate in their home environment for 7 days) in a double-blind, randomized, crossover design. The two experimental conditions will be separated by a 7-day period of return to smoking of participants' own brand of cigarette. On the first and last day of each of the two experimental conditions, participants will smoke the assigned RNC in the laboratory, and data on toxicant exposure (i.e., boost in exhaled carbon monoxide and plasma nicotine and cotinine; solanesol from smoked cigarette butts), subjective acceptability (i.e., subjective response; risk perceptions; relative reinforcing efficacy); and smoking compensation (i.e., smoking topography measures) related to the smoked RNC will be collected. During each 7-day period of exposure to the RNCs, participants will provide daily data on alcohol and nicotine use, nicotine withdrawal, smoking urge, and alcohol urge via telephone-based Interactive Voice Response technology. The strength of our study design is that we can evaluate both between-group (i.e., ARD vs. Non ARD) and within-person (i.e., RNC Low vs. Moderate) differences in response to RNCs and, furthermore, can examine whether increased nicotine withdrawal, smoking urge, and alcohol urge mediate the relation between decreased nicotine exposure and alcohol consumption. Results from this study will show what mechanisms underlying drinking and smoking may need to be addressed in future integrated interventions for both problems and will immediately inform the practical implementation of market-wide reductions in cigarette nicotine content among smokers with ARD.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 47
• Est. completion date: April 21, 2021
• Est. primary completion date: April 21, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 21 Years to 65 Years

Eligibility

Inclusion Criteria:

• Ages 21-65;
• Smokes = 10 cigarettes/day for = 2 years;
• Has no immediate plans to quit drinking or smoking; and
• Sufficient understanding of informed consent form and study procedures.

Exclusion Criteria:

• Has or is at-risk of serious alcohol-related consequences, defined as any of the

following:

1. Meets DSM-5 criteria for current alcohol use disorder with the presence of 6 or more symptoms (i.e., current severity of severe)

2. Has a Clinical Institute Withdrawal Assessment scale score of =8,

3. Self-report of history of seizures, delirium, or hallucinations during alcohol withdrawal;

4. Self-report of drinking to avoid withdrawal symptoms, or

5. Self-report of a history of alcohol withdrawal treatment.

• Women if pregnant, lactating, or not using a reliable form of birth control;
• Has current serious psychiatric disorder;
• Has DSM-5 current severe substance use disorder, other than nicotine;
• Has current use of smokeless tobacco, pipes, cigars, e-cigarettes, or nicotine replacement products;
• Displays clinically evident intoxication on any study visit, confirmed by breathalyzer test (breath alcohol level (BAL)>0.02 mg%);
• Has difficulties with blood draws or poor venous access; or
• Has significant smoking-related disease (by history).

Related Conditions & MeSH terms

• Alcohol Drinking
• Alcoholism
• Cigarette Smoking Toxicity

Intervention

Drug:
• Reduced nicotine cigarettes
Participants will be assigned to undergo two experimental conditions (i.e., exclusive smoking of RNC Low or Moderate in their home environment for 7 days) in a double-blind, randomized, crossover design. The two experimental conditions will be separated by a 7-day period of return to smoking of participants' own brand of cigarette.

Locations

Country	Name	City	State
United States	Battelle Memorial Institute	Baltimore	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
Battelle Memorial Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Alcohol drinks per day		7 days
Secondary	Toxicant exposure	(1) boost in (a) exhaled carbon monoxide, (b) plasma nicotine, and (c) plasma cotinine, and (2) solanesol after laboratory smoking	7 days
Secondary	Subjective acceptability	subjective response	7 days
Secondary	Smoking compensation	number of cigarettes per day during each 7-day period	7 days